{
  "id": 20761360,
  "title": "Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy",
  "url": "https://urgent.news/2026/11/19/predictive-biomarker-for-liver-cancer-associated-with-survival",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T14:10:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-biomarker-liver-cancer-survival-outcomes.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}